Increased risk of steatotic liver disease, major adverse liver outcomes, cardiovascular events and mortality in pheochromocytoma: a model of chronically elevated sympathetic tone

Clicks: 23
ID: 328632
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #76 of 122 articles by views in european journal of endocrinology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 122 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally, yet the contribution of autonomic dysfunction to its progression remains incompletely understood. Pheochromocytoma and paraganglioma (PPGL), characterised by excessive catecholamine production, provide a human model to investigate the impact of chronic sympathetic activation on MASLD and major adverse liver outcomes (MALO). Methods We conducted a retrospective cohort study using data from the TriNetX Network, including adults with PPGL (exposure) and essential hypertension (controls), defined using ICD-10 codes/anthropometry. Cohorts were propensity score matched (1:1) for demographic, metabolic and blood pressure–related variables and followed for five years from index diagnosis. The primary outcome was time to incident MASLD. Secondary outcomes included MALO, type 2 diabetes (T2D), major adverse cardiovascular events (MACE) and all-cause mortality. Survival analysis generated hazard ratios (HR) and 95% confidence intervals (95% CI). Results After matching, 45,595 patients were included in each arm. PPGL was associated with increased risk of incident MASLD (HR 1.48; 95% CI 1.38–1.58) and MALO (1.59; 1.44–1.76), including hepatic decompensation (1.73; 1.53–1.95) and hepatocellular carcinoma (2.18; 1.70–2.80), compared with essential hypertension. A modest increase in MACE was observed (1.13; 1.09–1.16), while incident T2D risk was not significantly different (1.02; 0.98–1.06). Pheochromocytoma and PPGL treated with α-adrenergic blockade demonstrated greatest cardiometabolic risk. Conclusion PPGL was associated with increased risk of MASLD, progressive liver complications, MACE and mortality, supporting a link between chronic catecholamine excess and adverse hepatic outcomes. These findings provide human evidence that sustained sympathetic overactivity may contribute to hepatic steatosis and progression.
Reference Key
openalex_W7213448556 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Alex E. Henney, Andrew Davison, Uazman Alam, Daniel J. Cuthbertson
Are you one of these authors? Claim your profile
Journal european journal of endocrinology
Year 2026
DOI
10.1093/ejendo/lvag176
URL
https://doi.org/10.1093/ejendo/lvag176
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.